The publication of research demonstrating the therapeutic potential of a company's drug candidate often leads to positive investor sentiment. This is because it represents progress in the drug's development pathway, potentially leading to successful commercialization and revenue generation. For Compugen, the focus on COM503 and its recognition in a reputable journal could attract investor interest, potentially driving up the stock price in the short term.